Fulgent Genetics Launches At-Home Neutralizing Antibody Test for COVID-19

Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it has launched an antibody test for COVID-19 which will specifically target neutralizing antibodies.